Joshua Mitchell

Cardiologist at Washington University in St. Louis. #CardioOnc, evidence-based medicine, prevention, patient advocacy. Army veteran (#RLTW). Opinions my own.

[markusathome @MarkusAtHome]

Immune Checkpoint Inhibitor–Associated Cardiovascular Toxic Effects by Drs.
@mayocvonc, @joshmitchellmd et al.

An International Cardio-Oncology Society Position Statement:

https://t.co/efX2eH93p0

[Joshua Mitchell @joshmitchellmd]

I am always in awe of the team we have on the @ICOSociety Scientific and Research Committee. Such a fantastic group of international collaborators. Really enjoyed working on this position statement with them. Great content in the manuscript and supplement!

#cardiooncology https://t.co/2lOpuNByk3

[International Cardio-Oncology Society @ICOSociety]

📰 HOT OFF THE PRESSES 📰

Immune Checkpoint Inhibitor (#ICIs) treatments are known to potentially cause harm to the heart, particularly through conditions like #myocarditis.

Today in @JAMAOnc, we stressed the importance of interdisciplinary collaboration as the best way to mitigate effects and protect the #hearts of #cancer patients.

Read the positioning statement: https://t.co/2SktP5Q75j

[Raja Zaghlol @RajaZaghlol]

Check out our publication in #CardioOncology. Atrial fibrillation/flutter in stem cell transplant patients. Prevalence, association with outcomes, and impact on healthcare resource-utilization/readmissions. @joshmitchellmd @Teebi_MD
https://t.co/E58ilZLFdR

[Joshua Mitchell @joshmitchellmd]

@RajaZaghlol, a fantastic @WashUCardiology fellow, led this impactful study on afib in stem cell tx patients. Patients with afib were 3-4x more likely to die in the hospital, and 50% more likely to die in 90 days after discharge. Congrats! @ICOSociety #cardioonc

[@SN_Oncology @SN_Oncology]

🚨Recently published in #CardioOncology

Atrial fibrillation or flutter in patients undergoing stem cell transplantation, in-hospital and post-discharge outcomes in a large nationwide sample across the United States🔍

#OpenAccess #CardiovascularHealth

👉https://t.co/K8p0JqgqCt

[Benjamin Kopecky @BKopeckyMDPhD]

3 years ago my good friend @MorenoMDPhD approached me about this crazy idea to fill a much needed gap in heart failure education (1/3).

[Joshua Mitchell @joshmitchellmd]

Congrats to Matt Lui, outstanding @WashUCardiology fellow, on his study showing that a visual review of CAC on NSCLC RAD planning CT was more predictive of CV events than Rad dose. Visual review ~ formal CAC score. #cardioonc @ICOSociety @SBRT_CR

https://t.co/AtKhO3kAaS

[Joshua Mitchell @joshmitchellmd]

Congrats to @RajaZaghlol for leading our contemporary review of CV complications from radiation therapy including historic trends and current recs. Always great to work with @carmenbergom @DrLPedersen and @yoo_sgkyle! #cardioonc @WashUCardiology

https://t.co/ymRjawVAfM

[Joshua Mitchell @joshmitchellmd]

Congrats to @gwalls89 for an excellent manuscript detailing the practice patterns and general uptake of guidelines in #radonc internationally. Interesting insights! #cardioonc @icosociety @gerryhanna

https://t.co/VjL5Wzj8pL

[Joshua Mitchell @joshmitchellmd]

Awesome work by @RajaZaghlol exploring the CV effects of CAR-T in the Medicare population. Well-deserved! Special thanks to @kejoynt, @dgermain21 and Elena Deych, among others as well! Looking forward to the manuscript! @WashUCardiology #cardioonc

[Raja Zaghlol @RajaZaghlol]

Proud to be selected as a YIA finalist in the #GCOS2024 presenting our work investigating MACE in older adults receiving CART therapy. Special thanks to @joshmitchellmd for exceptional mentoring. @ICOSociety

[Ana Barac, MD, PhD, FACC, FAHA @AnaBaracCardio]

Huge Congratulations w Thank you @JLiu_MSKCardOnc & @DrGuptaD! Phenomenal #MSKCardioOnc meeting moving #CardioOnc forward! @MSKCancerCenter @TeresaLpezFdez1 @drtarsh @dineshpmcc1 @Dr_Mike_Fradley @DrSFeldman @ninianlang @mayocvonc @joshmitchellmd @ICOSociety

[Joshua Mitchell @joshmitchellmd]

@DrSFeldman @MSKCME @genomics212 Thanks @DrSFeldman ! You have all planned an amazing symposium!!!! Glad I could contribute!

[Joshua Mitchell @joshmitchellmd]

Excellent symposium on #cardionc with a nice balance of presentations on the breadth of the field. Congrats to @JLiu_MSKCardOnc and @DrGuptaD and the rest of the planning committee. #mskcardionccme @MSKCancerCenter @WashUCardiology

[Stephanie Feldman @DrSFeldman]

Masterful review of radiation heart disease and optimal strategies for surveillance by @joshmitchellmd #MSKCardioOncCME @MSKCME @genomics212

[Joshua Mitchell @joshmitchellmd]

Look forward to seeing everyone on Saturday for a packed agenda on #amyloidosis! Great speakers from @WUSTLmed and @PennMedicine as well as our esteemed grad @CampbellMDPhD! Free registration for trainees and patients/families.
@Amyloidosisfdn @CyclingDoctor @WashUCardiology

[WashU Medicine Department of Medicine @WashUDeptMed]

The Continuing Medical Education - Amyloidosis 2024: Update on Best Practices for Early Detection and Treatment - will be Saturday, April 27th. It's designed for healthcare providers involved in the diagnosis or management of amyloidosis. @WUSTLmed

Info> https://t.co/L8tNDkvdR6

[Joshua Mitchell @joshmitchellmd]

Great partnering with @myocardialsoln + the team on this important study. MRI myocardial strain is the most sensitive way to detect early cardiotoxicity. Excited to determine how early detection can best guide cardioprotection to improve heart health. @WashUCardiology #cardioonc

[WashU Medicine Cardiovascular Division @WashUCardiology]

Register now for @WUSTLmed @WUDeptMedicine Amyloidosis 2024 Symposium on April 27th- free for trainees! For details and to register, visit https://t.co/0du2yU2f8L

[Han Zhu @HanZhuMD]

Excited to share this preprint. Serial, routine troponin-I screening in 428 consecutive patients treated with immunotherapy at our center was correlated with lower rates of grade 4-5 cardiovascular adverse events without a change in oncologic time on tx
https://t.co/tj9bRDjxhy

[Keith Stockerl-Goldstein, MD 😷 @CyclingDoctor]

Published in @Heart_BMJ --"Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society @ICOSociety statement"--an important step in improving care for our patients with #amyloidosis.
#CardioOnc @joshmitchellmd @WashUOnc #mmsm
https://t.co/WGpNcbZBzo

[Joshua Mitchell @joshmitchellmd]

Great having the chance to talk #cardioonc education with @nickwilcox, @vgzmd, @BenedicteLefeb1 and @JACCJournals. Check out the podcast below. 👇

https://t.co/YUWC5r2LMp

#jacccardioonc @WashUCardiology @WUSTLmed

[WashU Medicine Cardiovascular Division @WashUCardiology]

New Podcast from @JACCJournals Cardio-OncologyPulse featuring Dr. Joshua Mitchell, @joshmitchellmd highlighting education! @WUCardioFellows

https://t.co/daYZDOoLwN